Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of GST-HG151 in Healthy Volunteers
NCT05345964Phase 1Unknown
- Sponsor
- Fujian Cosunter Pharmaceutical Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GST-HG151 in Nonalcoholic steatohepatitis (NASH) and Liver Fibrosis (LF) (6 arms), sponsored by Fujian Cosunter Pharmaceutical Co., Ltd. Primary endpoints: Adverse Events at Day 20, Serious Adverse Events at Day 20 and 6 more. Status: unknown.
02
Drugs
GST-HG151
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT05345964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05345964.